c-MET Protein Overview: Sequence, Structure, Function and Protein Interaction

c-MET Protein Overview

Cooper et al. (1984) cloned a transforming gene from a chemically transformed human osteosarcoma-derived cell line and mapped it to 7p11.4-qter. Identity to all previously known oncogenes except ERBB (131550) was ruled out by the fact that they are encoded by other chromosomes; identity to ERBB is probably excluded by failure of direct hybridizations of the 2 probes. MET was the designation suggested by Cooper et al. (1984). Dean et al. (1985) showed that MET is in the tyrosine kinase family of oncogenes. It appeared to be most closely related in sequence to the human insulin receptor and ABL oncogene. From the sequence of MET cDNA, Park et al. (1987) concluded that this oncogene is a cell-surface receptor for a then unknown ligand. The c-Met protooncogene product is a receptor-like tyrosine kinase comprised of disulfide-linked subunits of 50 kD (alpha) and 145 kD (beta). In the fully processed c-Met product, the alpha subunit is extracellular, and the beta subunit has extracellular, transmembrane, and tyrosine kinase domains as well as sites of tyrosine phosphorylation.

c-MET protein family

Belongs to the protein kinase superfamily. Tyr protein kinase family.

c-MET protein name

Recommended name
Hepatocyte growth factor receptor
Short name
HGF receptor||SF receptor
Aliases
DFNB97, hepatocyte growth factor receptor, HGFR, RCCP2
Alternative name
HGF/SF receptor Proto-oncogene c-Met Scatter factor receptor Tyrosine-protein kinase Met

c-MET Protein Sequence

Species Human c-MET protein
Length 1390
Mass (Da) 155541
Sequence Human c-MET protein sequence
Species Mouse c-MET protein
Length 1379
Mass (Da) 153549
Sequence Mouse c-MET protein sequence
Species Rat c-MET protein
Length 1382
Mass (Da) 153941
Sequence Rat c-MET protein sequence

c-MET Protein Molecular Weight & PI

Hepatocyte growth factor receptor precursor (EC 2.7.10.1) (HGF receptor) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met) Homo sapiens (Human).

The parameters have been computed for the following feature

FT CHAIN 25-1390 Hepatocyte growth factor receptor.

Molecular weight (Da)

153050.23

Theoretical pI

6.88

c-MET Protein Structure

DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX
Deposited
2000-10-03   Released:  2000-12-06
Deposition Author(s)
Schiering, N., Casale, E., Caccia, P., Giordano, P., Battistini, C.
Organism(s)
Homo sapiens
Expression System
Escherichia coli
Experimental Data Snapshot
Method
X-RAY DIFFRACTION
Resolution
2.4000 Å
R-Value Free
0.270
R-Value Work
0.217
1FYR From PDB

Human c-MET protein Secondary structure

c-MET Protein Interaction

Recombinant c-MET Protein Feature

c-MET Protein, Human, Recombinant (ECD, His Tag)

High Purity
> 90 % as determined by SDS-PAGE
Low Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
High Activity
Measured by its binding ability in a functional ELISA . Immobilized recombinant human HGF at 10 μg/ml (100 μl/well) can bind biotinylated c-Met . The EC50 of biotinylated c-Met is 5.28 μg/ml.

Recombinant c-MET protein citations

Title
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity
Year
2013
Author
SA Olwill, C Joffroy, H Gille, E Vigna…
Journal
Molecular Cancer Therapeutics
Title
Anti-MET immunoPET for non-small cell lung cancer using fully human antibody fragments
Year
2014
Author
Li, K;Tavare, R;Zettlitz, KA;Mumenthaler, SM;Mallick, P;Zhou, Y;Marks, JD;Wu, AM;
Journal
Mol. Cancer Ther.
Title
Crystal Structure of Human Leukocyte Cell-derived Chemotaxin 2 (LECT2) Reveals a Mechanistic Basis of Functional Evolution in a Mammalian Protein with an M23 Metalloendopeptidase Fold
Year
2016
Author
Zheng, H;Miyakawa, T;Sawano, Y;Asano, A;Okumura, A;Yamagoe, S;Tanokura, M;
Journal
J. Biol. Chem.
Title
Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody
Year
2017
Author
Park, H;Kim, D;Son, E;Shin, S;Sa, JK;Kim, SH;Yoon, Y;Nam, DH;
Journal
Biochem. Biophys. Res. Commun.
Title
Simultaneous targeting of two distinct epitopes on MET effectively inhibits MET- and HGF-driven tumor growth by multiple mechanisms
Year
2017
Author
Grandal, MM;Havrylov, S;Poulsen, TT;Koefoed, K;Dahlman, A;Galler, GR;Conrotto, P;Collins, S;Eriksen, KW;Kaufman, D;Vande Woude, GF;Jacobsen, HJ;Horak, ID;Kragh, M;Lantto, J;Bouquin, T;Park, M;Pedersen, MW;
Journal
Mol. Cancer Ther.
Title
Triptolide-assisted phosphorylation of p53 suppresses inflammation-induced NF-κB survival pathways in cancer cells
Year
2017
Author
Zheng, L;Jia, J;Dai, H;Wan, L;Liu, J;Hu, L;Zhou, M;Qiu, M;Chen, X;Chang, L;Kim, JY;Reckamp, K;Raz, DJ;Xia, Z;Shen, B;
Journal
Mol. Cell. Biol.
Title
High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma
Year
2019
Author
Ma, Y;Zhang, M;Wang, J;Huang, X;Kuai, X;Zhu, X;Chen, Y;Jia, L;Feng, Z;Tang, Q;Liu, Z;
Journal
Front Oncol
Title
Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet
Year
2019
Author
Wu, X;Zhou, J;Wang, F;Meng, X;Chen, J;Chang, TS;Lee, M;Li, G;Li, X;Appelman, HD;Kuick, R;Wang, TD;
Journal
Sci Rep
Title
Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet
Year
2019
Author
Wu, X;Zhou, J;Wang, F;Meng, X;Chen, J;Chang, TS;Lee, M;Li, G;Li, X;Appelman, HD;Kuick, R;Wang, TD;
Journal
Sci Rep
Title
Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning
Year
2020
Author
Yoo, DK;Lee, SR;Jung, Y;Han, H;Lee, HK;Han, J;Kim, S;
Journal
Biomolecules
Title
A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
Year
2020
Author
Fujita, R;Blot, V;Wong, E;Stewart, C;Lieuw, V;Richardson, R;Banah, A;Villicana, J;Timmer, A;Coronella, J;Newman, R;Gymnopoulos, M;
Journal
Cancer Biol. Ther.
Title
A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
Year
2020
Author
Fujita, R;Blot, V;Wong, E;Stewart, C;Lieuw, V;Richardson, R;Banah, A;Villicana, J;Timmer, A;Coronella, J;Newman, R;Gymnopoulos, M;
Journal
Cancer Biol. Ther.
Title
A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
Year
2020
Author
Fujita, R;Blot, V;Wong, E;Stewart, C;Lieuw, V;Richardson, R;Banah, A;Villicana, J;Timmer, A;Coronella, J;Newman, R;Gymnopoulos, M;
Journal
Cancer Biol. Ther.
Title
A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
Year
2020
Author
Fujita, R;Blot, V;Wong, E;Stewart, C;Lieuw, V;Richardson, R;Banah, A;Villicana, J;Timmer, A;Coronella, J;Newman, R;Gymnopoulos, M;
Journal
Cancer Biol. Ther.

Bulk Order of Recombinant c-MET Protein

Please Leave Us a Message if you have any questions regarding bulk price quote of our products on the website, our customer specialist will get back to you in 24 hours by email.

Custom Recombinant Protein Production Service Features

  • Over 10 years' experience for 6000+ recombinant proteins production.
  • One-stop service from gene synthesis and vector construction to protein expression and purification.
  • Multiple protein expression systems: bacterial, yeast, baculovirus-insect and mammalian expression system.
  • Multiple purification systems (30+) to choose.
  • High R & D ability with over 1000 new proteins per year and quick problem-solving ability.
  • Close to 100 bioreactors with various volume between 2-1000 L to guarantee high-throughput and large-scale production.

Custom Recombinant Protein Production Service Advantages

  • High-efficiency expression vectors
  • High cell density culturing
  • Proprietary medium formulation
  • >6000 proteins expression and purification experience
  • High-efficiency expression vectors
  • High cell density culturing

Recombinant Protein Production Service Description

We offer one-stop services for recombinant protein production using our advanced protein expression platform technologies. Our full services include protein gene synthesis, protein codon optimization, protein expression vector design, large scale cell culture and fermentation, protein purification, and protein quality control testing. We offer significant cost saving advantages and record speed in protein expression and bulk production. We also have extensive experiences and expertise in handling various types of recombinant protein purification projects, with or without purification tags.